Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Stock analysts at SVB Leerink dropped their FY2025 earnings per share (EPS) estimates for shares of Marinus Pharmaceuticals in a research note issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of $1.75 for the year, down from their previous forecast of $1.80. SVB Leerink currently has a “Outperform” rating and a $27.00 price objective on the stock.
Several other brokerages have also commented on MRNS. Truist Financial increased their price objective on Marinus Pharmaceuticals from $35.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, March 22nd. StockNews.com initiated coverage on Marinus Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 26th. Cantor Fitzgerald raised their target price on Marinus Pharmaceuticals from $25.00 to $28.00 in a research note on Wednesday. Finally, JMP Securities raised their target price on Marinus Pharmaceuticals from $21.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday, March 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Marinus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.86.
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last issued its quarterly earnings data on Monday, March 21st. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.04. Marinus Pharmaceuticals had a negative return on equity of 121.57% and a negative net margin of 643.70%. The firm had revenue of $1.52 million during the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the prior year, the business posted ($0.55) EPS.
A number of hedge funds have recently bought and sold shares of MRNS. Suvretta Capital Management LLC boosted its holdings in Marinus Pharmaceuticals by 20.1% in the 4th quarter. Suvretta Capital Management LLC now owns 2,638,775 shares of the biopharmaceutical company’s stock worth $31,349,000 after buying an additional 441,349 shares during the last quarter. Jefferies Group LLC lifted its stake in Marinus Pharmaceuticals by 2,774.8% in the 3rd quarter. Jefferies Group LLC now owns 439,764 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 424,467 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $1,461,000. SG Americas Securities LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $806,000. Finally, Dimensional Fund Advisors LP lifted its stake in Marinus Pharmaceuticals by 91.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 88,385 shares of the biopharmaceutical company’s stock worth $1,050,000 after purchasing an additional 42,254 shares in the last quarter. Institutional investors own 85.95% of the company’s stock.
Marinus Pharmaceuticals Company Profile (Get Rating)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.